文献速递银屑病与炎症性皮肤病

BAT2206与乌司奴单抗治疗中重度银屑病三期研究:第2治疗期结果

A phase 3, randomized, double-blind, active-controlled clinical study to compare BAT2206, a ustekinumab biosimilar, with ustekinumab reference product in patients with moderate-to-severe psoriasis: Treatment period 2 results (post Week 28 to Week 52).
PubMed 文献 · J Am Acad Dermatol · 2025-08-09

BAT2206是乌司奴单抗(UST)的生物类似药。此前已报告第28周前(TP1)BAT2206与UST疗效等效且安全性相当。本文呈现TP2(第28周后至52周)结果:528例患者进入TP2,分为UST-UST、UST-BAT2206和BAT2206-BAT2206三组。次要疗效终点和不良事件在三组间无明显差异,UST血清浓度无显著差异,免疫原性相当,从UST转换至BAT2206未导致免疫原性增加。

要点

  • TP2中三组次要疗效终点和不良事件无明显差异。
  • UST血清浓度和免疫原性在三组间相当。
  • 从UST转换至BAT2206未增加免疫原性。

核心结论

  • TP2中三组结局相当,从UST转换至BAT2206无影响。

研究设计与样本

  • 三期随机双盲阳性对照临床研究,TP2纳入第28周达到PASI≥75的患者。
  • TP2共528例,UST-UST组133例,UST-BAT2206组131例,BAT2206-BAT2206组264例。

主要发现

  • 次要疗效终点和不良事件在三组间无明显差异。
  • UST血清浓度无显著差异。
  • 免疫原性相当,从UST转换至BAT2206未导致免疫原性增加。

临床怎么用

  • 支持BAT2206作为UST生物类似药在中重度银屑病维持治疗及转换治疗中的应用。

局限性

  • 无第52周之后的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: BAT2206 is being developed as a ustekinumab (UST) biosimilar. OBJECTIVES: Equivalent efficacy and comparable safety results of BAT2206 and UST in patients with moderate-to-severe psoriasis up to Week 28 (treatment period [TP] 1) have been reported previously. TP2 (post Week 28 to 52) results are presented here. METHODS: Patients achieving Psoriasis Area and Severity Index response (≥75) at Week 28 entered TP2. Qualified patients of the UST group in TP1 were re-randomized 1:1 into UST-BAT2206 or UST-UST groups, while qualified patients of the BAT2206 group continued with BAT2206 (BAT2206-BAT2206 group). In TP2, secondary efficacy endpoints, pharmacokinetics, safety, and immunogenicity were assessed at Week 32, 40, 44, and 52. RESULTS: A total of 528 patients entered TP2, of which 133, 131, and 264 were assigned to UST-UST, UST-BAT2206, and BAT2206-BAT2206 groups, respectively. The secondary efficacy endpoints and the adverse events showed no obvious differences across all 3 groups. There were no notable differences in the UST serum concentrations. Immunogenicity was comparable, and the switching from UST to BAT2206 did not lead to an increased immunogenicity. LIMITATIONS: No data collected after Week 52. CONCLUSION: Outcomes were comparable among the groups in TP2, with no impact from the UST-to-BAT2206 switch.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Man X, Zaharieva K, Pulka G, et al. A phase 3, randomized, double-blind, active-controlled clinical study to compare BAT2206, a ustekinumab biosimilar, with ustekinumab reference product in patients with moderate-to-severe psoriasis: Treatment period 2 results (post Week 28 to Week 52). J Am Acad Dermatol. 2025. PMID: 40784561. doi:10.1016/j.jaad.2025.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。